Repligen Corporation (RGEN)
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen Corporation: Still Navigating Through The Covid Cliff
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base through a series of acquisitions and new launches, reducing its reliance on any single customer. RGEN stock is down 60% from its highs in the summer of 2021, and Repligen has a pristine balance sheet.
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Officer Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Justin D.
Repligen (RGEN) Lags Q2 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Here's Why Repligen (RGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Dan Arias - Stifel Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Subbu Nambi - Guggenheim Securities Brendan Smith - TD Cowen Doug Schenkel - Wolf Research Matt Stanton - Jefferies Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter of 2025 Earnings Conference Call. My name is Dorwin, and I will be your coordinator.
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
